CBIO · Crescent Biopharma, Inc.

Track CBIO — free

$13.98 -0.34 (-2.37%)

Russell 2000 member Rebalance outlook locked

Market Cap

$548.24M

37.14M

Volume · Oct 5 76.06K Avg daily vol (3M) 380.11K

Up next

Next earnings call

Jan 25, 2027 Est · unconfirmed · in 16 wks

Latest filing: 10-Q

filed Jul 30, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

—

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

—

Year over year · more shares

Price change (1Y)

+19.0%

Trailing year

Short interest

9.2%

Latest settlement · 8.5 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Strong Sell

SellHoldBuy

Technical Sell Momentum Weak Sentiment Bullish Fundamentals Poor Quant / Vol Very High

Market backdrop VIX 15.3 · calm Equity put/call 0.58

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg −9%

below

Price vs 50-day avg −15%

below

RSI (14) 36

neutral

MACD trend Negative

52-week position 30%

mid-range

Momentum

relative strength

Weak

1-month return −30%

trailing

6-month return −20%

trailing

YTD return +21%

this year

Relative strength −33%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $17 › 200d $16 — 50d above 200d

Institutional flow Accumulating

+33% holders QoQ · +32 funds added

Insider flow Accumulating

Net +$12.4M over 90 days · 0% sells

Short interest Rising

9.17% of float · ▲ +7.4% MoM · 8.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

80 holders — near 1-yr high, broad support

Squeeze score 63

elevated · 0–100

Fundamentals

Poor

Revenue growth −100%

Y/Y

EPS growth −2%

Y/Y

Free cash flow $-72.5M

Quant / Vol

risk profile

Very High

Volatility 81%

annualized · 1-yr

Max drawdown −48%

past year

ATR 8.7%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell

3 · 3 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−9% Bearish

Price vs 50-day avg

−15% Bearish

RSI (14)

36 Neutral

MACD trend

Negative Bearish

52-week position

30% Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $17 › 200d $16 — 50d above 200d

Institutional flow Accumulating

+33% holders QoQ · +32 funds added

Insider flow Accumulating

Net +$12.4M over 90 days · 0% sells

Short interest Rising

9.17% of float · ▲ +7.4% MoM · 8.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

80 holders — near 1-yr high, broad support

Price context

position in its 52-week range

Range low $9 Now $14 · 30% Range high $27

vs 200-day avg -9% vs 50-day avg -15%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
CBIO Crescent Biopharma, Inc. this stock	$548.24M	+20.7%	-99.9%	—	9.2%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+11.3%	+46.2%	30.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$81.13B	-4.8%	+20.8%	19.5	2.5%
MRNA Moderna, Inc.	$79.40B	+544.3%	+4.3%	—	8.2%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

% held: 78.4%
Net QoQ: +4.0M sh
Top holder: FMR LLC

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Rising

Shares short

3.4M

Days to cover: 8.5d
Change: +234.8K sh

View

Short Volume

Short vol %

75%

As of: Oct 2, 2026

Short Total

View

Fails to Deliver

FTD shares

Value: $753
As of: Sep 2, 2026

View

Off-Exchange

Off-exchange %

51.8%

Week of: Aug 31, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net buying

Net (90d)

+$12.4M

Buyers / Sellers: 1 / 0

Buyers Sellers

View

Financials

Revenue (FY)

$10.8M

Net income (FY): $-153.9M
EPS diluted: $-59.00

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Sep 14, 2026
This year: 14

View

Proposed Sales

Value

$8.5K

Shares: 4.3K
Filed: May 17, 2023

View

Earnings & Events

Webcasts

Last webcast

Sep 14, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
CBIO	+2.4%	-29.8%	-20.4%	-1.9%	+20.7%
SPY	-0.2%	-0.5%	+12.2%	+0.9%	+12.9%
vs SPY	+2.6%	-29.3%	-32.6%	-2.8%	+7.9%

Key facts CIK 1253689 CUSIP G2545C104 13F (30d) 2 filings 2 filers Visit website Investor relations

CBIO · Crescent Biopharma, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance